UBS AM
CVAC

UBS AM’s CureVac CVAC Stock Holding History

UBS AM’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-201,329
Closed -$1.09M – 2361
2025
Q2 		$1.09M Sell
201,329
-78,327
-28% -$311K ﹤0.01% 2369
2025
Q1 		$775K Buy
279,656
+3,151
+1% +$11K ﹤0.01% 2401
2024
Q4 		$943K Sell
276,505
-661
-0.2% -$1.91K ﹤0.01% 2387
2024
Q3 		$815K Sell
277,166
-25,130
-8% -$82.8K ﹤0.01% 2484
2024
Q2 		$1.03M Buy
+302,296
New +$989K ﹤0.01% 2355
2022
Q2 		– Sell
-22,466
Closed -$441K – 2706
2022
Q1 		$441K Hold
22,466
– – ﹤0.01% 2499
2021
Q4 		$771K Sell
22,466
-3,209
-12% -$129K ﹤0.01% 2350
2021
Q3 		$1.4M Hold
25,675
– – ﹤0.01% 1997
2021
Q2 		$1.89M Buy
+25,675
New +$2.57M ﹤0.01% 1876

Other funds holding CVAC

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BA
Bridgewater Associates Westport, Connecticut $22.4B AUM 34.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM's CVAC Position: Q3 2025 in Review

UBS AM sold out of CureVac (CVAC) in Q3 2025, closing a stake of 201,329 shares — an estimated $1.09M sold.

UBS AM first reported a position in CVAC in Q2 2021 and held it in 9 quarters. The position peaked at $1.89M in Q2 2021. 94 funds tracked by Wall St. Rank hold CVAC as of Q3 2025.

  • UBS AM reported no remaining CureVac position as of Q3 2025 after selling out during the quarter.
  • UBS AM sold 201,329 CureVac shares in Q3 2025, an estimated $1.09M.
  • UBS AM first reported a position in CureVac in Q2 2021 and held it in 9 quarters.
  • UBS AM's CureVac position peaked at $1.89M in Q2 2021.
  • 94 funds tracked by Wall St. Rank held CureVac as of Q3 2025.

Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.